Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells - PubMed (original) (raw)
. 2005 Sep 1;106(5):1824-30.
doi: 10.1182/blood-2004-12-4918. Epub 2005 May 19.
Affiliations
- PMID: 15905192
- DOI: 10.1182/blood-2004-12-4918
Free article
Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells
Meike Burger et al. Blood. 2005.
Free article
Abstract
Growth and survival of chronic lymphocytic leukemia (CLL) B cells are favored by interactions between CLL and nontumoral accessory cells. CLL cells express CXCR4 chemokine receptors that direct leukemia cell chemotaxis. Marrow stromal cells or nurselike cells constitutively secrete CXCL12, the ligand for CXCR4, thereby attracting and rescuing CLL B cells from apoptosis in a contact-dependent fashion. Therefore, the CXCR4-CXCL12 axis represents a potential therapeutic target in CLL. We evaluated the most active CXCR4-specific antagonists (T140, TC14012, TN14003) for their capacity to inhibit CXCL12 responses in CLL cells. T140, or its analogs, inhibited actin polymerization, chemotaxis, and migration of CLL cells beneath stromal cells. CXCL12-induced phosphorylation of p44/42 mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription 3 (STAT3) was abolished by CXCR4 antagonists. TC14012 and TN14003 antagonized the antiapoptotic effect of synthetic CXCL12 and stromal cell-mediated protection of CLL cells from spontaneous apoptosis. Furthermore, we found that stromal cells protected CLL cells from chemotherapy-induced apoptosis. Treatment with CXCR4 antagonists resensitized CLL cells cultured with stromal cells to fludarabine-induced apoptosis. These findings demonstrate that CXCR4 blocking agents effectively antagonize CXCL12-induced migratory and signaling responses and stromal protection of CLL cells from spontaneous or fludarabine-induced apoptosis. As such, small molecular CXCR4 antagonists may have activity in the treatment of patients with this disease.
Similar articles
- Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.
Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova AV, Wierda WG, Keating MJ, Shokat KM, Burger JA. Niedermeier M, et al. Blood. 2009 May 28;113(22):5549-57. doi: 10.1182/blood-2008-06-165068. Epub 2009 Mar 24. Blood. 2009. PMID: 19318683 Free PMC article. - Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias.
Zeng Z, Samudio IJ, Munsell M, An J, Huang Z, Estey E, Andreeff M, Konopleva M. Zeng Z, et al. Mol Cancer Ther. 2006 Dec;5(12):3113-21. doi: 10.1158/1535-7163.MCT-06-0228. Mol Cancer Ther. 2006. PMID: 17172414 - Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1.
Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Burger JA, et al. Blood. 2000 Oct 15;96(8):2655-63. Blood. 2000. PMID: 11023495 - Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.
ten Hacken E, Burger JA. ten Hacken E, et al. Pharmacol Ther. 2014 Dec;144(3):338-48. doi: 10.1016/j.pharmthera.2014.07.003. Epub 2014 Jul 19. Pharmacol Ther. 2014. PMID: 25050922 Review. - CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment.
Burger JA, Kipps TJ. Burger JA, et al. Blood. 2006 Mar 1;107(5):1761-7. doi: 10.1182/blood-2005-08-3182. Epub 2005 Nov 3. Blood. 2006. PMID: 16269611 Review.
Cited by
- Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.
Ten Hacken E, Burger JA. Ten Hacken E, et al. Biochim Biophys Acta. 2016 Mar;1863(3):401-413. doi: 10.1016/j.bbamcr.2015.07.009. Epub 2015 Jul 17. Biochim Biophys Acta. 2016. PMID: 26193078 Free PMC article. Review. - Impact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia.
Patel V, Chen LS, Wierda WG, Balakrishnan K, Gandhi V. Patel V, et al. Leuk Lymphoma. 2014 Apr;55(4):899-910. doi: 10.3109/10428194.2013.819573. Epub 2013 Sep 10. Leuk Lymphoma. 2014. PMID: 23837491 Free PMC article. - C-X-C motif chemokine ligand 12-C-X-C chemokine receptor type 4 signaling axis in cancer and the development of chemotherapeutic molecules.
Yen JH, Chang CC, Hsu HJ, Yang CH, Mani H, Liou JW. Yen JH, et al. Tzu Chi Med J. 2024 May 27;36(3):231-239. doi: 10.4103/tcmj.tcmj_52_24. eCollection 2024 Jul-Sep. Tzu Chi Med J. 2024. PMID: 38993827 Free PMC article. Review. - Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling.
Burger JA, Montserrat E. Burger JA, et al. Blood. 2013 Feb 28;121(9):1501-9. doi: 10.1182/blood-2012-08-452607. Epub 2012 Dec 20. Blood. 2013. PMID: 23264597 Free PMC article. Review. - The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment.
Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG, Bhalla KN, Burger JA. Kim E, et al. Leukemia. 2020 Jun;34(6):1588-1598. doi: 10.1038/s41375-019-0682-7. Epub 2019 Dec 20. Leukemia. 2020. PMID: 31862959 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous